FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
November 7, 2025
Foley Viewpoints
Client Briefing: Texas Senate Bill 840 and Texas Senate Bill 2477 (89th Legislature, 2025 Session)
Texas S.B. 840 and S.B. 2477, effective September 1, 2025, significantly curtail how larger Texas cities regulate mixed-use and…
November 5, 2025
Foley Viewpoints
Securing Digital Supply Chains: Confronting Cyber Threats in Logistics Networks
Key Takeaways: On the Rise: Cyberattacks through the supply chain have increased by over 400% in recent years. Leaders need to take…
October 29, 2025
Foley Viewpoints
Long & Winding Road: New CFTC Chair
CFTC Commissioner Brian Quintenz was nominated to be the CFTC chair in February 2025; however, his nomination was officially withdrawn in September 2025. Michael Selig has confirmed reports that he was being nominated to lead the CFTC.